Clinical Trial Update: Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Acute Graft Versus-Host Disease [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating extracorporeal photoimmune therapy with UVADEX (amotosalen) for acute graft-versus-host disease was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• UVADEX (methoxsalen)

Snippet

Sponsor: Mallinckrodt | Conditions: Acute Graft-versus-Host Disease | Phase 3 | Status: TERMINATED